ESTRO 2024 - Abstract Book

S1835

Clinical - Mixed sites, palliation

ESTRO 2024

into short survivors (surviving <3 months), moderate survivors (surviving ≥ 3 months and <2 years), and long survivors (surviving ≥2 years) after (start of) radiotherapy. Descriptive statistics, baseline demographics and treatments characteristics were described, and PROs were collected. PROs were measured at baseline, at 4 and 8 weeks, and at 3, 6, 12, 18, and 24 months after (start of) treatment, and included the global quality of life score, emotional functioning and physical functioning using the EORTC QLQ Core 15 Palliative Care (C15-PAL) questionnaire. The QoL scores were linearly transformed to a 0-100 scale for all domains. Scores were compared to normative data of the general population.

Results:

At time of analysis, 2471 patients were included in the PRESENT cohort. Of those, 584 were excluded (e.g. enrolled after October 1, 2021, or consent withdrawal) resulting in 1887 patients included in the analysis. In total, 418 patients (22%) were short survivors, 883 (47%) were moderate survivors, and 586 (31%) were long survivors (41% alive). Overall, median follow-up was 9 months [IQR 3-30], mean age was 67.2 years (±10.6 years), and 1124 male (60%) and 763 female (40%) patients were included. Most patients had one or multiple bone metastases originating from prostate (n=478, 25%), lung (n=444, 24%), or breast (n=369, 20%) cancer. These baseline characteristics were similar across the three survival groups. Long-term survivors presented more often with good performance status (i.e. ECOG score of 0) than short and moderate survivors (30% vs. 6% and 12%, respectively), with a single metastasis (16% vs. 4% and 4%, respectively), and/or with no other (non-bone) metastases (58% vs. 23% and 38%, respectively). Long-term survivors were more frequently treated with stereotactic body radiotherapy treatment regimens (22% vs. 2% and 8%, respectively). A total of 1565 patients (63%, n=330 short, n=733 moderate, n=502 long survivors) provided PROs. Across all three domains, short-term survivors scored very poorly and also moderate survivors had a lower QoL than the long survivors (Figure 1, panel a b c). Moderate and long-term survivors experienced a substantial increase in QoL between baseline and 4 weeks after radiotherapy, and this improvement persisted for long-term survivors over a 24-month period. Long-term survivors had a similar global quality of life and emotional functioning as the general population. A total of 145 patients (8%) survived ≥ 5 years. Their QoL scores in the first 24 months after radiotherapy were very good, and for all three domains comparable to that of the general population (Figure 1, panel d e f).